AS/Spondyloarthritis
3 years 6 months ago
#Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease burden is less (compared to radiographic-AxSpa)!" Dr. Atul Deodhar @RheumNow
3 years 6 months ago
Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla
3 years 6 months ago
#Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two ends of the spectrum -- same disease! @RheumNow https://t.co/r0fTtp3Uip
3 years 6 months ago
#EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is similar with equal burden of disease. @RheumNow https://t.co/tm9Y6OB5TY
3 years 6 months ago
Comparison of disease activity and PROs in AxSpA vs. AxPsA
⭐️AxSpA ⬆️ uveitis and IBD
⭐️AxPsA ⬆️enthesitis and dactylitis
⭐️AxSpA pts ⬆️pain, spinal pain PROs
⭐️Fatigue and work impairment did not differ in AxSpA vs AxPsA
Abs#OP0049 #EULAR2021 @RheumNow https://t.co/wGD6IA5ahb
3 years 6 months ago
Secukinumab effective in AS patients, irrespective of gender
AQUILA 52 week study
⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women
⭐️women had overall higher disease burden in global functioning and depressive mood
POS0899
#EULAR2021 @RheumNow
3 years 6 months ago
C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA
⭐️82% ⬇️ in uveitis flare event
⭐️reduction in axSpA disease activity
⭐️no new safety signals
POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY
3 years 6 months ago
Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx
3 years 6 months ago
In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weight were negative factors in remission. Abstract #OP0052 #EULAR2021 @RheumNow https://t.co/X4wN1wIGfX https://t.co/DKBIXmEmki
3 years 6 months ago
Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern similar in 4/6 BASDAI components regardless of gender. Females reports ^ fatigue, males report ^ spinal pain. Abstract# OP0051 #EULAR2021 @RheumNow https://t.co/U8T8JEWwCp https://t.co/yNP6PuA8PD